{
  "as_of": "2026-11-14",
  "slug": "duchenne",
  "title": "杜氏肌失養症新藥全景",
  "title_en": "Duchenne Muscular Dystrophy Drug Landscape",
  "scope": "基因治療、外顯子跳躍、細胞與抗發炎治療分路徑比較；基因型、年齡、步行能力與試驗終點不同，不以跨試驗數字排療效。",
  "scope_en": "Gene therapy, exon skipping, cell therapy and anti-inflammatory approaches serve different populations. Genotype, age, ambulation and endpoints prevent an across-trial efficacy ranking.",
  "short_answers": [
    "截至 2026-11-14，Sarepta Elevidys、NS Pharma Viltepso、Italfarmaco Duvyzat 與 Catalyst 的 Agamree 均有美國核准，但適用族群及監管路徑不同。",
    "Capricor 於 2026-11-10 公布 HOPE-3 延伸期：從安慰劑轉用 deramiocel 後，上肢功能下降速度較其先前年份減慢 76%；這是開放標籤、跨期比較。",
    "Capricor 於 2026-11-10 確認 deramiocel 的 FDA 審查目標日為 2026-11-22；結果將決定細胞治療是否進入已核准梯隊。"
  ],
  "short_answers_en": [
    "As of 2026-11-14, Sarepta’s Elevidys, NS Pharma’s Viltepso, Italfarmaco’s Duvyzat and Catalyst’s Agamree had US approvals, with different eligible populations and regulatory pathways.",
    "Capricor reported on 2026-11-10 that upper-limb decline slowed by 76% after placebo patients switched to deramiocel in the HOPE-3 extension, an open-label cross-period comparison.",
    "Capricor confirmed on 2026-11-10 that the FDA target action date for deramiocel was 2026-11-22; the decision will determine whether cell therapy joins the approved field."
  ],
  "asia_section": "日本新藥的美國子公司 NS Pharma 持有 Viltepso；藥物適用可跳躍第 53 外顯子的特定基因型，屬加速核准，臨床效益仍須確認。Capricor 與日本新藥的商業合約爭議另列為權利風險，歷史合作與現行權利風險分開判讀。日本資產的基因型適用範圍及確認性試驗，須與其他全身性治療分開判讀。",
  "asia_section_en": "Nippon Shinyaku’s US subsidiary NS Pharma holds Viltepso for mutations amenable to exon 53 skipping; its accelerated approval requires confirmation of clinical benefit. Capricor’s disclosed dispute with Nippon Shinyaku is a separate rights risk, so historical cooperation is not treated as an uncontested current entitlement. The Japanese program’s eligible genotypes and confirmatory evidence must be assessed separately from broader systemic therapies.",
  "selection_inputs": [
    "R12"
  ],
  "assets": [
    {
      "section": "approved",
      "trials": [],
      "date": "2025-11-14",
      "sources": [
        "https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-takes-action-new-boxed-warning-acute-serious-liver-injury-and-acute-liver-failure-following"
      ],
      "source_ids": [
        "dmd-elevidys"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Elevidys／delandistrogene moxeparvovec",
      "asset_en": "Elevidys / delandistrogene moxeparvovec",
      "company": "Sarepta",
      "company_en": "Sarepta",
      "country": "美國",
      "country_en": "US",
      "mechanism": "AAV 微型肌失養蛋白基因治療",
      "mechanism_en": "AAV micro-dystrophin gene therapy",
      "route": "靜脈輸注",
      "route_en": "Intravenous",
      "stage": "美國已核准，族群縮限",
      "stage_en": "US approved; restricted population",
      "indication": "4 歲以上可步行 DMD",
      "indication_en": "Ambulatory DMD, age 4+",
      "latest": "2025-11-14 FDA 加肝損傷黑框警語並移除不可步行族群",
      "latest_en": "FDA boxed liver warning and removal of non-ambulatory indication on 2025-11-14"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1ffff9a8-6d6a-4dcb-8493-1b6cc3a5d123"
      ],
      "source_ids": [
        "dmd-viltepso"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Viltepso／viltolarsen",
      "asset_en": "Viltepso / viltolarsen",
      "company": "日本新藥／NS Pharma",
      "company_en": "Nippon Shinyaku / NS Pharma",
      "country": "日本／美國",
      "country_en": "Japan / US",
      "mechanism": "外顯子 53 跳躍 ASO",
      "mechanism_en": "Exon 53-skipping ASO",
      "route": "靜脈輸注",
      "route_en": "Intravenous",
      "stage": "美國加速核准",
      "stage_en": "US accelerated approval",
      "indication": "可跳躍外顯子 53 的 DMD",
      "indication_en": "DMD amenable to exon 53 skipping",
      "latest": "標籤要求驗證臨床效益；不視為全基因型治療",
      "latest_en": "Clinical benefit requires confirmation; not all-genotype treatment"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "2024-03-21",
      "sources": [
        "https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-duvyzat"
      ],
      "source_ids": [
        "dmd-itf"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Duvyzat／givinostat",
      "asset_en": "Duvyzat / givinostat",
      "company": "Italfarmaco／ITF Therapeutics",
      "company_en": "Italfarmaco / ITF Therapeutics",
      "country": "義大利／美國",
      "country_en": "Italy / US",
      "mechanism": "HDAC 抑制劑",
      "mechanism_en": "HDAC inhibitor",
      "route": "口服",
      "route_en": "Oral",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "6 歲以上 DMD",
      "indication_en": "DMD, age 6+",
      "latest": "FDA 主要試驗共 179 人；不是基因替代治療",
      "latest_en": "FDA pivotal study: 179 participants; not gene replacement"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://www.catalystpharma.com/approved-products"
      ],
      "source_ids": [
        "dmd-catalyst"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Agamree／vamorolone",
      "asset_en": "Agamree / vamorolone",
      "company": "Catalyst（北美）／Santhera",
      "company_en": "Catalyst (North America) / Santhera",
      "country": "美國／瑞士",
      "country_en": "US / Switzerland",
      "mechanism": "改良類固醇",
      "mechanism_en": "Modified corticosteroid",
      "route": "口服",
      "route_en": "Oral",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "2 歲以上 DMD",
      "indication_en": "DMD, age 2+",
      "latest": "北美商業化由 Catalyst；仍需類固醇安全監測",
      "latest_en": "Catalyst commercializes in North America; corticosteroid precautions apply"
    },
    {
      "section": "clinical",
      "trials": [],
      "date": "2026-11-10",
      "sources": [
        "https://www.capricor.com/investors/news-events/press-releases/detail/359/capricor-therapeutics-reports-third-quarter-2026-financial"
      ],
      "source_ids": [
        "dmd-capricor"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "deramiocel／CAP-1002",
      "asset_en": "deramiocel / CAP-1002",
      "company": "Capricor",
      "company_en": "Capricor",
      "country": "美國",
      "country_en": "US",
      "mechanism": "異體心球衍生細胞",
      "mechanism_en": "Allogeneic cardiosphere-derived cells",
      "route": "靜脈輸注",
      "route_en": "Intravenous",
      "stage": "FDA 審查中",
      "stage_en": "FDA review",
      "indication": "擬聚焦大於 9 歲上肢功能受損 DMD",
      "indication_en": "Proposed focus: upper-limb impairment in DMD age >9",
      "latest": "目標日 2026-11-22；OLE 跨期上肢下降少 1.56 分（76%）；與日本新藥合約爭議持續",
      "latest_en": "Target 2026-11-22; OLE cross-period upper-limb decline 1.56 points less (76%); Nippon Shinyaku dispute ongoing"
    },
    {
      "section": "clinical",
      "trials": [],
      "date": "2026-07-29",
      "sources": [
        "https://dynetx.gcs-web.com/news-releases/news-release-details/dyne-therapeutics-reports-second-quarter-2026-financial-results"
      ],
      "source_ids": [
        "dmd-dyne"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "z-rostudirsen／DYNE-251",
      "asset_en": "z-rostudirsen / DYNE-251",
      "company": "Dyne",
      "company_en": "Dyne",
      "country": "美國",
      "country_en": "US",
      "mechanism": "肌肉遞送外顯子 51 跳躍藥",
      "mechanism_en": "Muscle-delivered exon 51-skipping therapy",
      "route": "靜脈輸注",
      "route_en": "Intravenous",
      "stage": "FDA 優先審查；確認性三期",
      "stage_en": "FDA Priority Review; confirmatory Phase 3",
      "indication": "可跳躍外顯子 51 的 DMD",
      "indication_en": "DMD amenable to exon 51 skipping",
      "latest": "公司 7/29 公告審查目標 2027-01-21，非核准結果",
      "latest_en": "Company’s July 29 release set target 2027-01-21; not an approval outcome"
    }
  ],
  "number_checks": [
    [
      "D1",
      "HOPE-3 開放延伸期跨期下降速度減慢",
      "76%",
      "dmd-capricor",
      "76%"
    ],
    [
      "D2",
      "上述上肢量表下降差值",
      "1.56 分",
      "dmd-capricor",
      "1.56"
    ],
    [
      "D3",
      "deramiocel 審查目標日",
      "2026-11-22",
      "dmd-capricor",
      "November 22, 2026"
    ],
    [
      "D4",
      "Duvyzat FDA 主要試驗總人數",
      "179 人",
      "dmd-itf",
      "179"
    ],
    [
      "D5",
      "Elevidys 現行步行族群年齡下限",
      "4 歲",
      "dmd-elevidys",
      "4 years"
    ]
  ],
  "not_listed_unconfirmed": [],
  "not_listed_note": "",
  "not_listed_note_en": "",
  "summary_expected": {
    "total": 6,
    "approved": 4,
    "clinical": 2,
    "phase2_3": 0,
    "discontinued": 0,
    "asia": 1,
    "taiwan": 0
  }
}
